-
1Academic Journal
Authors: M. Sh. Khubutia, O. N. Rzhevskaya, K. E. Lazareva, М. Ш. Хубутия, О. Н. Ржевская, К. Е. Лазарева
Source: Transplantologiya. The Russian Journal of Transplantation; № 2 (2009); 9-14 ; Трансплантология; № 2 (2009); 9-14 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2009-0-2
Subject Terms: пероральные сахароснижающие препараты, glucose intolerance, tacrolimus, cadaveric renal allotransplantation, pancreatic allotransplantation, glycosylated hemoglobin, oral sugar-lowering drugs, нарушение толерантности к глюкозе, такролимус, аллотрансплантация трупной почки, аллотрансплантация поджелудочной железы, гликолизированный гемоглобин
File Description: application/pdf
Relation: https://www.jtransplantologiya.ru/jour/article/view/250/312; Hathaway D.K., Tolley E.A., Blakely M.L. et al. Development of an index to predict post-transplant diabetes mellitus. Clin Transplant 1994;7:330—8.; Friedman E.A., Shyh T., Beyer M.M. et al. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 1985;5: 196—202.; Vincenti F., Friman S., Scheuermann E. et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transp 2007;7:1506—14.; Howard A. Management of new-onset diabetes mellitus in the kidney transplant recipient. Medscape Transplant 2004; 14 Jul.; Thomas M.C, Moran J., Mathew T.H. et al. Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes. BMC Nephrology 2000;1:1.; Pourmand G., Ebrahimi M.R., Mehrsai A.R., Taheri M. Patient blood glucose levels before and after kidney transplantation. Transplant Proc 2000;32(3):566—8.; Min C., Kang E., Yu S.H. et al. Advanced glycation end products induce apoptosis and pro-coagulant activity in cultured human umbilical vein endothelial cells. Diabetes Res Clin Pract 1999;46(3): 197—202.; Pavlovic D., Van de Winkel M., Van der Auwera B. et al. Effect of interferongamma and glucose on major histo-compatibility complex class I and class II expression by pancreatic beta- and non-beta-cells. J Clin Endocrinol Metab 1997;82(7):2329—36.; Foster K.J., Alberti K.G., Binder C. et al. Lipid metabolites and nitrogen balance after abdominal surgery in man. Br J Surg 1979;66(4):242—5.; Spencer C.M., Goa K.L., Gillis J.C. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997;54: 925—75.; Jindal R.M., Sidner R.A., Milgrom M.L. Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf 1997;16: 242—57.; Pirsch J.D., Miller J., Deierhoi M.H. et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997;63:977—83.; Cavaille-Coll M.W., Elashoff M.R. Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1998;65:142—3.; Marchetti P., Navalesi R. The metabolic effects of cyclosporine and tacrolimus. J Endocrinol Invest 2000;23:482—90.; Heisel O., Heisel R., Balshaw R., Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004;4;583—95.; Jain A., Khanna A., Molmenti E.P. et al. Immunosuppressive therapy. Surg Clin North Am 1999;79:59—76.; Johnson C., Ahsan N., Gonwa T. et al. Randomized trial of tacrolimus in combination with azathioprine or mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000;63;834—41.; Lazzaro C., McKechnie T., McKenna M. Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses. J Nephrol 2002;15:580—8.; Vincenti F., Jensik S.C., Filo R.S. et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002;73:775—82.; Weir M.R., Fink J.C. Risk for post-transplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999;34:1—13.; Hirano Y., Fujihira S., Ohara K. et al. Morphological and functional changes of islets of Langherans in FK506-treated rats. Transplantation 1992;53:889—94.; Martin F., Bedoya F.J. Mechanisms of action of cyclosporine A on islet alfa-and beta cells. Effects on cAMP and calcium dependent pathways. Life Sci 1991;49:1915—21.; Redmond J.B., Olson L.K., Armstrong M.B. et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996;98: 2786—93.; Ishizuka J., Guiuzza K.K., Wassmuth Z. et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islet. Transplantation 1993;56:1486—90.; Noguchi N., Takasawa S., Nata K. et al. Cyclic ADP-ribose binds to FK506 binding protein 12.6 to release calcium++ from islet microsome. J Biol Chem 1997;272:3133—6.; Lanerolle R.D., de Abrew K., Fernando D.J., Sheriff M.H. Posttransplant diabetes in Sri Lanka. Transplant Proc 1996;28:1945—7.; Berwerck S., Kahl A., Bechstein W. et al. Clinical use of the euglicemic hyperinsulinemic clamp for diagnosis of tacrolimusinduced insulin resistance after combined pancreas-kidney transplantation. Transplant Proc 1998;30:1944—5.; Basadonna G., Montorsi F., Dakizaki K., Merrell R.C. Cyclosporine A and islet function. Am J Surg 1988;156:191—3.; Bani Sacchi T., Bani D., Filipponi F. et al. Immunocytochemical and ultra structural changes of islet cells in rats treated longterm with cyclosporine at immunotherapeutic doses. Transplantation 1990;49:982—7.; Van Hoff J.P., Christiaans M.H., Ven Duijnhoven E.M. et al. Glucose metabolic disorder after transplantation. Am J Transplant 2007;7:1435—6.; Ciancio G., Burke G., Gaynor J. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004;77:252—8.; Maes B.D., Kuypers D., Messian T. et al. Post-transplan-tation diabetes mellitus in FK506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation 2001;72:1655—61.; Pagano G., Cavalco-Perin P., Cassader M. et al. An in vivo and in vitro study of the mechanism of prednisoneinduced insulin resistance in healthy subjects. J Clin Invest 1983;72:1814—20.; Shapiro R., Jordan M.L., Scantlebury V.P. et al. A prospective, randomized trial of FK506/prednisone vs FK506/azathioprine/prednisone in renal transplant patients. Transplant Proc 1995;27:814—7.; Christiansen E., Andersen H., Rasmusse K. et al. Pancreatic b-cell function and glucose metabolism in human segmental pancreas and kidney transplantation. Am Physiol Soc 1993;264(3):441—9.; Andrews R.C., Wolker B.R. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci 1999;96:513—23.; Henriksen J.E., Alford F., Ward G.M., Beck-Nielsen H. Risk and mechanism for dexamethazone-induced deterioration of glucose tolerance in non-diabetic first degree relatives of NIDDM patients. Diabetologia 1997;40:1439—48.; Hjelmesaeth J., Hartmann A., Kosstad J. et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997;64:979—83.; Jawad F., Rizvi S.A. Post-transplant diabetes mellitus in live-re-lated renal transplantation. Transplant Proc 2000;32:1888.; Boots J.M., Van Duijnhoven E.M., Christiaans M.H. et al. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002;13:221—7.; Vanrenterghem Y. Strategies to reduce or replace steroid dosing. Transplant Proc 1999;31 (Suppl 8A):7—10.; Christiansen E., Tibell A., Volund A.A. et al. Metabolism of oral glucose in pancreas transplant recipients with normal and impaired glucose tolerance. J Clin Endocrinol Metab 1997;82:2299—307.; Gruessner R.W. Tacrolimus in pancreas transplantation: a multi-center analysis. Tacrolimus Pancreas Study Group. Clin Transplant 1997;11:299—312.; Gruessner R.W., Burke G.W., Stratta R. et al. A multi-center analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996;61:261—73.; Sumrani N.B., Delaney V., Ding Z. et al. Diabetes mellitus after renal transplantation in the cyclosporine era: an analysis of risk factors. Transplantation 1991;51:343—7.; Rao M., Jacob C.K., Shastry J.C. Post-renal transplant diabetes mellitus: a retrospective study. Nephrol Dial Transplant 1992;7:1039—42.; Keen H., Jarret R.J., Mc Cartney P. The ten-year follow-up of the Bedford survey (1962—1972): glucose tolerance and diabetes. Diabetologia 1982;22:73—8.; Vesco L., Busson M., Bedrossian J. et al. Diabetes mellitus after renal transplantation. Transplantation 1996;61:1475—8.; Kasiske B.L., Sneyder J.J., Gilbertson D., Matas A.J. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2002;2(Suppl 3):225.; Knoll G.A., Bell R.C. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. Br Med J 1999;318:1104—7.; Parikh C., Klem P., Wong C., Chan L. Obesity as an independent predictor of posttransplant diabetes mellitus (PTDM). Am J Transplant 2002;2(Suppl 3):420.; De Mattos A.M., Prather J., Al-Uzri A. et al. Autosomal dominant polycystic kidney disease (ADPKD) as risk factor for the development of posttransplant diabetes mellitus (PTDM). Am J Transplant 2002;2:359.; Cosio F.G., Pesavento T.E., Kim S. et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002;62:1440—6.; Revanur V.K., Jardine A.G., Kingsmore D.B. et al. Influence of diabetes mellitus on patients and graft survival in recipients of kidney transplantation. Clin Transplant 2001;15:89—94.; Thomas M.C., Mathew P.H., Russ G.R. et al. Early perioperative glycemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation 2001;72:1321—4.; Klahr S., Levey A.S., Beck G.J. et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group. N Engl J Med 1994;330:877—84.; Noble N.A., Border W.A. Angiotensin II in renal fibrosis. Should TGF-beta rather than blood pressure be the therapeutic target? Semin Nephrol 1997;17:455—66.; Miles A.M., Sumrani N., Horowitz R. et al. Diabetes mellitus after renal transplantation. Transplantation 1998;65:380—4.; Schneider D.J., Nordt T.K., Sobel B.E. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993;42:1—7.; Maser R.E., Wolfson S.K. Jr., Ellis D. et al. Cardiovascular disease and arterial calcification in insulin-dependent diabetes mellitus: interrelations and risk factor profiles. Arterioscler Thromb 1991;11:958—65 [Abstract].; Laakso M., Pyorala K., Scarlund H., Voutilainen E. Lipid and lipoprotein abnormalities associated with coronary heart disease in patients with insulin-dependent diabetes mellitus. Arteriosclerosis 1986;6:679— 84 [Abstract].; Raine A.E.G. Cardiovascular complications after renal transplantation. In: P.J. Morris (ed.). Kidney transplantation: principles and practice. Philadelphia: PA, Saunders; 1988. p. 575—601.; Hjelmeseth J., Hartmann A., Midvedt K. et al. Metabolic cardiovascular syndrome after renal Transplantation. Nephrol Dial Transplant 2001;16:1047—52.; Von Kiparsky A., Frei D., Uhlschmid G. et al. Post-transplant diabetes mellitus in renal allograft recipients: a matched pair control study. Nephrol Dial Transplant 1990;5:220—5.; Chiu M.Y., Sprague S.M., Bruce D.S. et al. Analysis of fracture prevalence in kidneypancreas allograft recipients. J Am Soc Nephrol 1998;9:677—83.; Marchetti P. Strategies for risk reduction and management of post-transplant diabetes mellitus. Transplant Proc 2001;33(Suppl 5A):27—31.; https://www.jtransplantologiya.ru/jour/article/view/250